Blocking the proliferation of activated HSCs by boosting apoptosis, cutting ECM synthesis, and shutting down the release of TGF-β are counted among the pharmacological effects of IFN-α, responsible for the observed improvement of liver fibrosis in BDL rats (Du et al., 2007). This evidence concerns the gene TGFB1 and Hepatic fibrosis.